Judith Brandt
Family Medicine · Camino, CANPI 1750363966
Payments from drug & device makers
Across 117 payments — averaging $28.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$682
- AstraZeneca$385
- Amgen$358
- GSK$310
- Biohaven Pharmaceuticals, Inc.$248
- Boehringer Ingelheim$242
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,29198%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $682 |
| AstraZeneca | 7 | $385 |
| Amgen | 6 | $358 |
| GSK | 5 | $310 |
| Biohaven Pharmaceuticals, Inc. | 6 | $248 |
| Boehringer Ingelheim | 11 | $242 |
| Astellas Pharma US Inc | 8 | $238 |
| Nestle Healthcare Nutrition Inc. | 5 | $122 |
| Corcept Therapeutics | 5 | $113 |
| Gilead | 2 | $102 |
| Novartis | 4 | $101 |
| Madrigal Pharmaceuticals | 1 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $72 |
| Lilly USA, LLC | 3 | $71 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Recordati_rare_diseases_inc. | 1 | $42 |
| Grifols USA, LLC | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Pfizer | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$236
- NURTEC ODT$124
- BREZTRI$122
- AREXVY$122
- AIRSUPRA$114
How this compares
$3,371 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 42 | $54,284 |
| Repatha SureclickEvolocumab | 32 | $42,392 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $29,780 |
| VeozahFezolinetant | 20 | $16,385 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $14,511 |
| LinzessLinaclotide | 12 | $14,125 |
| TradjentaLinagliptin | 11 | $12,739 |
| Novolog FlexpenInsulin Aspart | 13 | $3,660 |
| Buprenorphine | 12 | $3,644 |
| Celecoxib | 28 | $2,384 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 27 | $2,017 |
| Ezetimibe | 60 | $1,764 |
| Gabapentin | 47 | $1,460 |
| Rosuvastatin Calcium | 78 | $1,418 |
| Levocetirizine Dihydrochloride | 17 | $1,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $71 | $54,28442 claims |
| GSKTrelegy Ellipta | $310 | $29,78021 claims |
| Astellas Pharma US IncVeozah | $238 | $16,38520 claims |
| AbbVieLinzess | $682 | $14,12512 claims |
| Boehringer IngelheimTradjenta | $242 | $12,73911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Camino
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.